The administrative incidence of non-affective psychoses in Friesland and Twente

GGZ Friesland, afdeling Wetenschappelijk Onderzoek & Opleiding, Sixmastraat 2, 8901 BS Leeuwarden.
Tijdschrift voor psychiatrie 02/2008; 50(10):637-43.
Source: PubMed


Research into the risk factors for schizophrenia has once again drawn attention to the geographical differences in the incidence and gender distribution of schizophrenia. The incidence - as recorded by the mental health care services - of non-affective psychotic disorders in the Netherlands is unknown.
To ascertain the mental-health-care recorded incidence of non-affective psychotic disorders in Friesland and Twente in 2002.
The medical files of all adults who made their first contact with mental health care services in 2002 (n = 6,477) via two clinics in the Netherlands were screened for psychotic symptoms. All patients with psychotic symptoms (n = 242) were included and the clinical diagnosis was recorded. Thirty months later the most recent clinical diagnosis was recorded again. results Within six months of their first contact 75 patients were diagnosed with non-affective disorder. This diagnosis was still valid after 30 months. These results demonstrate an incidence of 2.2/10,000 inhabitants. The male-female ration was 1.8:1. The incidence of psychotic disorder did not differ significantly between the two regions under study.
The incidence found corresponds to the incidence reported in earlier Dutch studies; it lies on the 75th percentile of the cumulative incidence given in an international review.

Download full-text


Available from: Lex Wunderink, Jul 18, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotics are approved treatment for severe conditions and have serious side effects. Antipsychotics are often prescribed off-label. Although a substantial proportion of antipsychotics are prescribed in primary care, it is largely unknown what motivates the general practitioner (GP) to initiate antipsychotic treatment. Therefore, we sought to examine the relation between pre-defined, licensed as well as off-label, reasons for antipsychotic treatment and the initiation of this treatment by the GP as well as report registration and incidence of antipsychotic treatment in general practice. In a case-control study, 723 patients selected from an electronic database and with a new antipsychotic prescription were compared with 3615 controls receiving any other new prescription. Using logistic regression, six pre-defined categories of International Classification of Primary Care (ICPC) codes ('psychosis', 'depression and anxiety', 'sleeping disorders', 'acute stress and surmenage', 'dementia' and 'somatic indications') were associated with initiating antipsychotic treatment. All, including off-label, categories were significantly related to initiating antipsychotic treatment. The incidence of initiating antipsychotic therapy was 1.28 per 1000 persons per year (95% confidence interval: 1.09, 1.48). GPs registered an ICPC code in 50% and prescribed typical antipsychotics in 90% of the cases. Prescription of atypical antipsychotics increased almost threefold over the study period. The results suggest that GPs prescribe antipsychotics off-label. Despite serious side effects and relatively infrequent occurrence in Dutch general practices, GPs seem imprecise in underpinning and registrating the initiation of antipsychotic treatment. GPs increasingly prescribe atypical antipsychotics although the prescription of typical antipsychotics still dominates.
    Journal of Evaluation in Clinical Practice 02/2011; 17(1):12-7. DOI:10.1111/j.1365-2753.2009.01352.x · 1.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the effect of withdrawal of antipsychotic treatment on relapse risk in remitted first-episode schizophrenia patients. First-episode 1-year stable and remitted outpatients with a schizophrenic disorder were randomly allocated to continuation of their antipsychotic regimen for at least 6 months (N = 9), or gradual withdrawal (N = 11). Primary outcome was the difference in cumulative relapse-free survival at 9 months. Recruitment was terminated prematurely on 26 October 2005. The cumulative relapse-free survival was 88% (SE = 0.12) in the continuation and 18% (SE = 0.12) in the discontinuation group (P = 0.001) at 9 months follow-up. Discontinuation of antipsychotic medication markedly increases the risk of relapse in stable remitted first-episode schizophrenia patients. In future studies the topics of safety monitoring and sampling of patients should receive extra attention.
    International Journal of Psychiatry in Clinical Practice 06/2011; 15(2):128-34. DOI:10.3109/13651501.2010.534801 · 1.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence for an association between duration of untreated illness (DUI) with clinical and functional outcome or brain volume (change) in schizophrenia patients is inconclusive. We aimed to investigate the relationship between DUI, outcome and brain volume at illness onset or brain volume change during the first five years of the illness in first-episode patients. Magnetic resonance images were acquired at baseline (T0) and after 5-year (T5) of 57 schizophrenia patients. Correlations were calculated in patients between brain volume (change), DUI and outcome variables. We found no significant correlation between DUI and brain volume (change) in schizophrenia patients. A longer DUI was significantly correlated with higher PANSS scores at T0 and T5, and with higher scores on the Camberwell Assessment of Need scale at T5. Baseline volume of the cerebrum and lateral ventricles, and cerebellum volume (change) were associated with PANSS scores at T0 and T5. Although clinical outcome is associated with both brain volume (change) and DUI, we found no evidence for a relationship between DUI and brain volume (change). DUI and baseline brain volume or 5-year brain volume (change) seem to explain different parts of the variation in clinical outcome.
    Schizophrenia Research 08/2011; 132(1):84-90. DOI:10.1016/j.schres.2011.07.018 · 3.92 Impact Factor
Show more